{"id":"NCT02472964","sponsor":"Mylan Inc.","briefTitle":"Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca.","officialTitle":"A Multicenter, Double-Blind, Randomized, Parallel-Group, Phase III Study of the Efficacy and Safety of Hercules Plus Taxane Versus Herceptin® Plus Taxane as First Line Therapy in Patients With HER2-Positive Metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-07","primaryCompletion":"2016-03","completion":"2018-08","firstPosted":"2015-06-16","resultsPosted":"2018-10-30","lastUpdate":"2022-02-14"},"enrollment":500,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Trastuzumab","otherNames":["Herceptin©;"]},{"type":"BIOLOGICAL","name":"MYL- 1401O","otherNames":["Hercules"]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"Herceptin© + Taxane","type":"ACTIVE_COMPARATOR"},{"label":"MYL- 1401O + Taxane","type":"EXPERIMENTAL"}],"summary":"A multicenter, double-blind, randomized, parallel-group, Phase III study of the efficacy and safety of Hercules( Myl 1401O, Mylan Trastuzumab) plus taxane versus Herceptin® plus taxane as first line therapy in patients with HER2-positive metastatic breast cancer.","primaryOutcome":{"measure":"Primary Endpoint : Compare Best Overall Response Rate (ORR) (According to Response Evaluation Criteria in Solid Tumor [RECIST] 1.1 Criteria) at Week 24 of MYL-1401O Plus Taxane Versus Herceptin® Plus Taxane in the ITT1 Population","timeFrame":"from time of First treatment to week 24","effectByArm":[{"arm":"Herceptin© + Taxane","deltaMin":0,"sd":null},{"arm":"MYL-1401O Trastuzumab + Taxane","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":null},"locations":{"siteCount":92,"countries":["Brazil","Chile","Georgia","Hungary","India","Latvia","Peru","Romania","Russia","Serbia","Slovakia","South Africa","Thailand","Turkey (Türkiye)","Ukraine"]},"refs":{"pmids":["34125340","27918780"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":91,"n":246},"commonTop":["Alopecia","Neutropenia","Diarrhea","Asthenia","Nausea"]}}